Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2
Mesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and trans...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2020/8892189 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550898889392128 |
|---|---|
| author | Karen J. Juárez-Navarro Eduardo Padilla-Camberos Néstor Fabián Díaz Ariel Miranda-Altamirano N. Emmanuel Díaz-Martínez |
| author_facet | Karen J. Juárez-Navarro Eduardo Padilla-Camberos Néstor Fabián Díaz Ariel Miranda-Altamirano N. Emmanuel Díaz-Martínez |
| author_sort | Karen J. Juárez-Navarro |
| collection | DOAJ |
| description | Mesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and transfer of therapeutic molecules via exosomes. Nowadays, there are more than a thousand registered clinical trials related to MSC application around the world, highlighting MSC role on difficult-to-treat high-incidence diseases such as the current COVID-19, HIV infections, and autoimmune and metabolic diseases. Here, we summarize a general overview of MSCs and their therapeutic mechanisms; also, we discuss some of the novel clinical trial protocols and their results as well as a comparison between the number of registries, countries, and search portals. |
| format | Article |
| id | doaj-art-4540d1d29f894eb7883605f6610d233e |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-4540d1d29f894eb7883605f6610d233e2025-02-03T06:05:34ZengWileyStem Cells International1687-966X1687-96782020-01-01202010.1155/2020/88921898892189Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2Karen J. Juárez-Navarro0Eduardo Padilla-Camberos1Néstor Fabián Díaz2Ariel Miranda-Altamirano3N. Emmanuel Díaz-Martínez4Biotecnología Médica y Farmacéutica Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, MexicoBiotecnología Médica y Farmacéutica Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, MexicoDepartamento de Fisiología y Desarrollo Celular, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, MexicoDepartamento de Atención a Niños con Quemaduras, Hospital Civil de Guadalajara, MexicoBiotecnología Médica y Farmacéutica Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, MexicoMesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and transfer of therapeutic molecules via exosomes. Nowadays, there are more than a thousand registered clinical trials related to MSC application around the world, highlighting MSC role on difficult-to-treat high-incidence diseases such as the current COVID-19, HIV infections, and autoimmune and metabolic diseases. Here, we summarize a general overview of MSCs and their therapeutic mechanisms; also, we discuss some of the novel clinical trial protocols and their results as well as a comparison between the number of registries, countries, and search portals.http://dx.doi.org/10.1155/2020/8892189 |
| spellingShingle | Karen J. Juárez-Navarro Eduardo Padilla-Camberos Néstor Fabián Díaz Ariel Miranda-Altamirano N. Emmanuel Díaz-Martínez Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2 Stem Cells International |
| title | Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2 |
| title_full | Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2 |
| title_fullStr | Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2 |
| title_full_unstemmed | Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2 |
| title_short | Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2 |
| title_sort | human mesenchymal stem cells the present alternative for high incidence diseases even sars cov 2 |
| url | http://dx.doi.org/10.1155/2020/8892189 |
| work_keys_str_mv | AT karenjjuareznavarro humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2 AT eduardopadillacamberos humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2 AT nestorfabiandiaz humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2 AT arielmirandaaltamirano humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2 AT nemmanueldiazmartinez humanmesenchymalstemcellsthepresentalternativeforhighincidencediseasesevensarscov2 |